Ado-trastuzumab emtansine – The monoclonal drug conjugate in human epidermal growth factor receptor 2-positive breast cancer
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer comprises around 20%–25% of breast cancers. With the discovery of trastuzumab, there was a marked improvement in the survival of patients with HER2-positive breast cancer both in curative and metastatic settings. However, patient...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2020-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=2;spage=218;epage=220;aulast= |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|